← Leaderboards
Douglas Thomas Dieterich
Mount Sinai School Of Medicine Of Nyu
$1,765,604
Attributed
$3,424,490
Total exposure
10
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $706.1K · FY2010–14$1M$750K$500K$250K$0
'10
'11
'12
'13
'14
Funding mix
By agency
NIH$3,424,490 · 10
By mechanism
R01$3,317,773 · 1
M01$106,717 · 9
Top collaborators
- Andrea D. Branch5 shared
Most similar at Mount Sinai School Of Medicine Of Nyu
Same institution · by research overlap
- Andrea D. Branch$14,715,515
- Thomas W Mittag$3,871,776
- Catherine L Clelland$7,598,878
- Randall Griepp$6,718,072
- David A Simpson$225,172
Others in their field
Top investigators on “Human Subject”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- George R Seage · Abt Associates, Inc.$172,422,660
- Jay Arnold Tischfield · Rutgers, The State Univ Of N.J.$160,455,836
- Jeffrey P Krischer · University Of South Florida$155,493,283
- Charles A Coltman · Southwest Oncology Group$154,811,913
Research focus
Human SubjectClinical ResearchHuman Therapy EvaluationAntiviral AgentsHiv InfectionsClinical TrialsImmune ResponseFatigueVirus Infection MechanismAids TherapyDrug Screening /EvaluationAntiaids AgentAcquired Immunodeficiency SyndromeAnti-InflammatoryAdultBoneCardiovascular Risk FactorCaringAids/Hiv ProblemCaucasiansCalciumCalcium IntakeAdherence (Attribute)Calcium Metabolism
Grant awards (14)
Optimizing Vitamin D Treatment in HIV/AIDS: An RCT$662,522
R01 · FY2014 · DA
Optimizing Vitamin D Treatment in HIV/AIDS: An RCT$611,032
R01 · FY2013 · DA
Optimizing Vitamin D Treatment in HIV/AIDS: An RCT$659,845
R01 · FY2012 · DA
Optimizing Vitamin D Treatment in HIV/AIDS: An RCT$678,246
R01 · FY2011 · DA
Optimizing Vitamin D Treatment in HIV/AIDS: An RCT$706,128
R01 · FY2010 · DA
Adult AIDS Clinical Trials Group Longitudinal Linked Randomized Trials (ALLRT)..$36,547
M01 · FY2004 · RR
ACTG A5068 - A Randomized Phase I/II Pilot Study of Intermittent Withdrawal o...$29,240
M01 · FY2004 · RR
ACTG A5030-PHASE III, PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND TRIAL OF VALGANCIC..$19,004
M01 · FY2004 · RR
ACTG A5127-PHASE II, CONTROLLED TRIAL COMPARING THE EFFICACY OF ADEFOVIR DIP...$7,311
M01 · FY2004 · RR
ACTG A5015 - Phase II Exploratory Study Examining Immunologic and Virologic I...$5,846
M01 · FY2004 · RR
ACTG 362-Trial to Determine the Effiacy of Azithromycin Prophylaxis...$4,386
M01 · FY2004 · RR
ACTG 372-Phase II Study of Prolongation of Virologic...Rollover for ACTG 320$1,463
M01 · FY2004 · RR
ACTG 142 - PATHOPHYSIOLOIC STUDY OF DEVELOPMENT OF DISTAL SYMMETRICAL POLYNEU...$1,460
M01 · FY2004 · RR
ACTG A5090-Phase II, Placebo Controlled, Double-Blind Study of the Selegiline...$1,460
M01 · FY2004 · RR